Loading stock data…
HLN
$9.38+0.14 (+1.52%)
Market ClosedLast close May 1
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Haleon plc in the Healthcare sector is trading at $9.38. The stock is currently 18% below its 52-week high of $11.42, remaining 3.1% below its 200-day moving average. Technical signals show neutral RSI of 35 and bearish MACD signal, explaining why HLN maintains its current current market pressure. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 35) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$9.38
Potential Upside
7%
Whystock Fair Value$10.04
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus5 analysts
Buy
Mean target$11.74+25.2%
Range$10.00 – $13.85
Fundamentals
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$41.64B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
18.72
Beta
Defensive asset. Lower volatility than the S&P 500.
0.33
Div Yield
Strong income play. Yield provides a meaningful total return floor.
204.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
10.15%
Volume
Today's trading volume
7.27M
Recent News
Haleon (HLN) Appoints Richard Manso as US Chief Marketing Officer to Drive Consumer Agility
Haleon (NYSE:HLN) is one of the best IPO stocks to buy in 2026. On April 27, Haleon appointed Richard Manso as its new US Chief Marketing Officer. Reporting to Nathalie Gerschtein, CEO of US & President of North America, Manso is tasked with accelerating the company’s transition into a more agile, consumer-centric organization. His leadership […]
Haleon Q1 Earnings Call Highlights
Haleon (NYSE:HLN) reported 2.2% organic revenue growth in its first-quarter trading update, as management pointed to continued pressure on consumer confidence and a weaker-than-usual cold and flu season. The company reiterated its full-year outlook, while highlighting ongoing productivity-driven mar
Haleon hit by weak cold season but strong toothpaste sales keep outlook on track
Haleon PLC (LSE:HLN, NYSE:HLN) reported modest sales growth in the first quarter as strength in oral health was offset by a weak cold and flu season. The owner of brands including Panadol, Advil, Theraflu and Sensodyne said organic revenue rose 2.2% in the three months to March, with price...
Futura Medical refines strategy and evolves commercial model after tough 2025
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX), the consumer healthcare company behind erectile dysfunction gel Eroxon, said it has refined its strategy and is evolving its commercial model following a comprehensive strategic review. In its full-year results statement, the told investors it...
FTSE 100 Live: Stocks sink as oil pushes above $120, GSK and Haleon fall on results
FTSE 100 down 119 points at 10,213 Oil prices top $117 AstraZeneca, GSK, Lloyds, Halfords, SJP, Jet2 results out DCC in talks over private equity bid 5.30pm: Stocks struggle The FTSE 100 finished Wednesday’s session down 119 points at 10,213 as oil prices surged amid renewed...